News from RSC Medicinal Chemistry

We are delighted to announce Professor Mike Waring as the new Editor-in-Chief of RSC Medicinal Chemistry. Chair of Medicinal Chemistry at Newcastle University and Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit, Mike has worked mainly in the areas of diabetes and oncology, and his work has contributed to the discovery of 14 drug candidates. He has made significant contributions to the field, most notably in property-based optimisation, covalent inhibition, novel binding modes and new methods of hit generation. He also brings his extensive experience from industry as a Principal Scientist at AstraZeneca.

Mike says, “RSC Medicinal Chemistry is one of the premier medicinal chemistry journals and we look forward to continuing to publish cutting edge science with the highest standards of rigour. I hope that the work published in the journal will lead to the continued dissemination and evolution of best practice in our discipline that will drive our ability to deliver new therapies more effectively.”

We are very much looking forward to working together to ensure the journal grows from strength to strength in the coming years under Mike's leadership.

We must say a huge thank you to Gerhard Ecker, who retires as Editor-in-Chief, for all his invaluable contributions during this time. Gerhard has been instrumental to RSC Medicinal Chemistry's development and growth, navigating the journal through a time of significant change including the ongoing pandemic and our title change.

Finally, on behalf of all at the journal, we would like to take this opportunity to thank all of our authors, referees, readers, and Editorial and Advisory Board members for their continued support of, and contributions to RSC Medicinal Chemistry.

Katie Lim and Mike Waring

---